Sosei Commences Phase I For Oropharyngeal Candidiasis
This article was originally published in PharmAsia News
Executive Summary
Sosei Group Corp wholly owned subsidiary, Sosei Co., Ltd. has initiated a Japanese Phase I trial for SO-1105 (miconazole lauriad) for the treatment of oropharyngeal candidiasis in immune-compromised patients.